blue cross glp 1 Blue Shield Drops Coverage of GLP-1 Obesity Drugs IBX joins other insurers in

Piraccini, B., Scarci, F., Jansat, J., Falqus, M., Otero, R., Tamarit, M., Galvn, J., Tebbs, V., Massana, E., & Study Group, T

The drug suppresses appetite and promotes satiety, possibly leading to weight loss

Among food sources, plant sources (e.g., beans, peas, lentils, whole grains), dairy, seafood, eggs, and lean poultry should generally be encouraged based on their links to general health, with red and processed meats considered in moderation or minimized given links to type 2 diabetes, cardiovascular disease, and colorectal cancer in general populations

Oral semaglutide expanded access for people who prefer tablets over injections

In the STEP clinical trials, semaglutide 2.4 mg (Wegovy) demonstrated average weight loss of approximately 15% of initial body weight over 68 weeks when combined with lifestyle interventions